Profil
Christopher J.
Barden has held positions as the Chief Executive Officer at Treventis Corp.
and as the Chief Operating Officer & Director at DeNovaMed, Inc.
Postes actifs de Christopher J. Barden
| Sociétés | Poste | Début |
|---|---|---|
Treventis Corp.
 Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Directeur Général | - |
DeNovaMed, Inc.
 DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Directeur des opérations | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Health Technology |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |